KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
This product will be manufactured at Lupin's Pithampur facility in India
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Subscribe To Our Newsletter & Stay Updated
